Trinity Biotech PLC - Amendment to Credit Agreement and Convertible Note Issuance

Trinity Biotech PLC has entered into a second amendment to its Sixth Amended and Restated Credit Agreement. This amendment includes an additional $5,000,000 term loan and the issuance of a convertible promissory note to Perceptive Credit Holdings III, L.P. The convertible note allows for conversion into American Depositary Shares (ADSs) at 97% of the volume-weighted average price, with a floor price of $1.03, subject to certain ownership limitations. Additionally, an agreement with Perceptive Credit Holdings II, L.P. allows for the satisfaction of a $5,000,000 payment obligation through the conversion into ADSs. This amendment also addresses a $15,000,000 contingent payment obligation, replacing it with a $7,500,000 payment, also convertible into ADSs. The company has agreed to file a resale registration statement for these potential issuances by January 14, 2026. The overall aim is to strengthen the company's capital structure and support growth initiatives.